Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum

Infection and Immunity

Volumn 64, Issue 12, 1996, Pages 5225-5232

  Castagliuolo, Ignazio ^a   Thomas Lamont, J ^a   Nikulasson, Sigfus T ^b   Pothoulakis, Charalabos ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; MANNITOL; PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; ILEUM; INTESTINE BRUSH BORDER; INTESTINE MUCOSA PERMEABILITY; INTESTINE SECRETION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SACCHAROMYCES BOULARDII;

EID: 10544226189     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.64.12.5225-5232.1996     Document Type: Article

References (39)

1. Bartlelt, J. G., T. W. Chang, M. Gurwith, S. L. Gorhach, and A. U, Onderdonk. 1978 Antibiotic associated pseudomembranous colitis due to toxinproducing clostridia. N. Engl. J. Med. 298:531-534.
2. Bartlett. J, G., A. B. Onderdonk. R. L Clsneros. and D. L. Kasper. 1978. Clindamycin-associated culitis duo to a toxin-producing species of Clastridium in hamsters, J. Infect. Dis. 136:701-705.
3. Buts, J.-P., P. Bernasconl, M. Craynest, P. Maldague, and K. DeMeyer. 1986. Rusponse of human and rat intestinal mucosa to oral administration of Saccharomyces boulardi. Pediatr. Res. 20:192-196.
4. Buts, J.-P., P. Bernasconi, J.-H. Vaerman, and C. Dive. 1990. Stimulation of secretory IgA and secretory component of imunoglobulins in small intusline of rats treated with Saccharomyces Boulardi. Dig. Dis. Sci. 35:251-256.
5. Buls, J.-P., G. Corthler, and M. Delmee. 1993. Saccharomyces baulardi for Clostridium difficile-associated enteropathies in infants. J. Pediatr. Gastroenterol. Nutr. 16:419-425.
6. Castaglluolo, I., J. T. LaMont, R. Letourneau, C. P. Kelly, C. J. O'Keane, A. Jaffer, T. C. Theoharides, and C. Puthoulakis. 1994. Neuronal involvement in the intestinal effects of Closiridium difficile toxin A and Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 107:657-665.
7. 6a. Castagliuolo, I., C. Pothoulakis, and J. T. LaMont. Unpublished data.
8. Castex, F., G. Corthier, S. Jouvert, G. W. Elmer, J. Gulbal, F. Lucas, and M. Bastidel. 1989. Prevention of pseudomembranous cecitis by Sacchromyces boulardii topographical histology of the mucosa. bacterial counts and analysis of toxin production. Microecol. Ther. 19:241-250.
9. Castex, F., G. Corthier, S. Jouvert, G. W. Elmer, F. Lucas, and M. Bastide. 1990. Prevention of Clastridium difficile-induced experimental pseudomembranous colitis by Saccharomyses boulardii: a scanning electron microscopic study. J.Gen.Microbiol. 136:1085-1089.
10. Corthier, G., F, Dubos, and R. Ducluzeau. 1986. Prevention of Closiridium difficile mortality in gnotobiotic mice by Saccharomyces Boulardii. Can. J. Microbiol. 32:894-896.
11. Corthier, G., M. C. Muller, T. D. Wilkins, D, Lyerly, and R. L'Haridon. 1991. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clastridium difficile toxin A. Infect. Immun. 59:1192-1195.
12. Dove, C, H., S.-Z. Wang, S. B. Price, C. J. Phelps, D. M, Lyerly, T. D. Wilkins, and J. L. Johnson. 1990. Molecular characterization of the Closiridium difficile toxin A gene. Infect. Immun. 58:480-488.
13. Eglow. R., C. Pothoulukis, S. Itzkowitz, E. J. Israel, C. J. O'Keane, D. Gong, N, Gau, L. Xu, A. Walker, and J. T. LaMont. 1992. Diminished Clastridium difficile toxin A sensitivity in newborn rabbit ilcum is associated with decreased toxin A receptor. J. Clin. Invest. 90:822-829.
14. Elmer, G. W., and G. Corthier. 1990. Modulation of Clastridittm difficile induced mortality us a function of the dose and the viability of the Saccharomyces boulardii used as a preventive agent in gnotobiolic mice. Can. J. Mierobiol. 37:315-317.
15. Elmer, G. W., and L. V. McFarland. 1987. Suppression by Sacchramyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob. Agents Chemother. 31:129-131.
16. Kelly, C, P., C, Pothoulakis, and J. T. LaMont. 1994. Clastridium difficile colitis. N. Engl. J. Med. 330:257-262.
17. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
18. 14C in polyacrylatmide gels by fluorography. Eur. J. Biochem. 56:335-341.
19. Lyerly, D. M., P. E. Carrlg, and T. D. Wilkins. 1989. Susceptibility of Clostridium difficile toxins A and B to trypsin and chymotrypsin. Microb. Ecol. Health Dis. 2:219-221.
20. Massot, J., O. Sanchez. R. Asloin, and A. L. Parodi. 1984. Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. Arzneim-Forsch. 34:794-797.
21. McFarland, L. V. 1996. Sacchramyces boulardii is not Saccharomyces cerevisiae. Clin. Infect. Dis. 22:200-201. (Letter.)
22. McFarland, L. V., M. E. Mulligan, R. Y. Kwok, and W. E. Stamm. 1988. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320:204-210.
23. McFarland, L. V., C. M. Surawlcz, G. W, Elmer, K. A. Moyer, S. A, Melcher, R. Greenberg, and K. Bowen. 1993. Multivariate analysis of the clinical efficacy of a biotherapeutic agent. Saccharomyces boulardii for the proven- lion of antibiotic-associated diarrhea. Am. J. Epidemiol. 138:649. (Abstract.)
24. McFarland. L. V., C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. Muyer, S. A, Melcher, K. E. Bowen, J. Cox, Z. Noorani, G. Hamilton, M. Rubin, and D. Greenwald. 1994. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Cloutndiiim difficile disease. JAMA 271:1913-1918.
25. Pothoulakls, C., I. Castagliuolo, J. T. LaMont, A. Jaffer, J. C. O'Keane, M. Snider, and S. E. Leeman. 1994. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc. Natl. Acad. Sci. USA 91:947-951.
26. Pothoulakls, C., F. Karmell, C. P. Kelly, R. Eliakim, M. A. Joshi, C. J. O'Keane, I. Castagliuolo, J. T. LaMont, and D. Rachmilewitz. 1993. Ketotifen inhibits Clostridium difficile toxin A-induccd enteritis in rat ileum. Gastroenterology 105:701-707.
27. Pothoulakls, C., C. P. Kelly, M. A. Joshi, N. Gao, C. J. O'Keane, I. Castaglluolo, and J. T. LaMont. 1993. Saccharomyces boulardii inhibits Clastridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108-1115.
28. Pothoulakls, C., J. T. LaMont, R. Eglow, N. Gao, J. B. Rubbins. T. C. Theoharides, and B. F, Dickey. 1991. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J. Clin. Invest. 88:119-125.
29. Powers, J. C., S. Odake, J. Oleksyszyn, T. Ueda, B. Buduszek, and C.-M, Kam. 1993. Pruteases-structures, mechanism and inhibitors. Agents Actions 42(Suppl.):3-18.
30. Rlegler, M., R. Sedivy, C. Pothoulakls, G. Hamilton, J. Zacheri, G. Bischof, E. Consentini, W. Fell, R. Schiesset, J. T. LaMont, and E. Wenzl. 1995. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitra. J. Clin. Invest. 95:2004-2011.
31. 14C-labellcd hemoglobin. Anal. Biochem. 42:214-221.
32. Sullivan, N. M., S. Pellet, and T. D. Wilkins. 1982. Purification and characterization of toxins A and B from Clostridium difficile. Infect. Immun. 35: 1032-1040.
33. Surawicz, C. M., G. W. Elmer, P. Specimen, L. V. McFarland, J. Chinn, and G. van Beile. 1989. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study, Gastroenterology 96:981-988.
34. Toothaker, R. D., and G. W. Elmer. 1984. Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii, Antimicrob, Agents Chemother. 26:552-556.
35. Torres, J. F., E. Jennische, S. Lange, and I. Lonnroth, 1990. Emerotoxins from Clastridium difficile; diarrhocogenic potency and morphological effects in the rat intestine. Gut 31:781-785.
36. Torres, J. F., and I. Lonnroth. 1988. Comparison of methods for the production and purification of toxin A from Clostridium difficile. FEMS Microbiol. Lett. 52:41-16.
37. Triadafilopoulos, G., C. Pothoulakls, M. O'Brien, and J. T. LaMont. 1987. Differential effects of Clostridium difficile toxins A and B on rabbit ilcum. Gastroenterology 93:273-279.
38. Triadafilopoulos, G., C. Pothoulakls, R. Weiss, C. Glarapaolo, and J. T. LaMont. 1989. Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology 97:1186-1192.
39. Wilkins, T. D., and K. D. Tucker. 1989. Clostridium difficile toxin A (enterotoxin) uses Gal alpha-l-3Gal betal-4GlcNAc as a functional receptor. Microecol. Ther. 19:225-227.